Combination Gefitinib, Everolimus Not Associated with Significant Antitumor Activity
the Cancer Therapy Advisor take:
Patients with castration-resistant prostate cancer (CRPC) receiving a combination of gefitinib and everolimus did not demonstrate significant antitumor activity, according to an article published online in the journal Cancer.
This study consisted of two phases: phase 1 consisted of 10 patients with CRPC and two patients with glioblastoma who were administered 250 mg of gefitinib daily with a weekly dose of everolimus (30, 50, or 70 mg); phase 2 consisted of 27 patients who were administered gefitinib with everolimus (70 mg).
Results showed patients in phase 1 did not experience any pharmacokinetic interactions or dose-limiting toxicities. However, 18 out of 27 patients (67%) in phase 2 stopped receiving treatment before the 12-week evaluation point due to progression observed through prostate-specific antigen (PSA) levels (n=6), imaging (n=5), or due to a toxicity of grade 2 or higher (n=7).
Out of the total 37 patients with CRPC, 13 (35%) had rapidly increasing PSA levels after treatment initiation, which declined after discontinuing treatment.
Furthermore, a decrease in the standardized uptake value was observed using fluorodeoxyglucose positron emission tomography 24 to 72 hours after beginning treatment. This decrease was reported as being consistent with mammalian target of rapamycin (mTOR) inhibition in 27 of the 33 (82%) assessable patients—out of these 27 patients, 20 (74%) experienced a corresponding rise in PSA levels.
Castration-resistant prostate cancer patients receiving gefitinib and everolimus did not demonstrate antitumor activity.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma